inclusion criteria confirmed covid-19 (positive polymerase chain reaction (pcr) for covid-19 from any specimen) patients older than 18 years old and younger than 85 years old. bmi higher than 20 but lower than 40 patients with hypoxemia related to viral pneumonia (covid-19) requiring oxygen or nasal high flow therapy (to maintain spo2 above 92%) without criteria for immediate intubation or need for other respiratory supports (cpap, non-invasive ventilation). initiation of oxygen supplementation < 72 hours egfr (ckd epi) > 30 ml/min/1.73m2 serum troponin i < 80 ng/l heart rate ≥ 55 bpm if beta blockers or calcium channel blocker nondihydropyridine are used, and ≥ 60 bpm in the other patients exclusion criteria medical conditions level of care b (unless patient agrees to intubation at study enrollment), c or d (patient admitted for palliative care; or physician is not committed to life-sustaining therapies) no spo2 signal available (only if freeo2 apparatus is used) patient agitation (only if freeo2 apparatus is used) severe untreated sleep apnea history of or currently active primary or secondary immunodeficiency recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, class iii/iv heart failure known presence of mobitz type ii second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker child-pugh score class c pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured during screening persistent hypotension. prior/concomitant therapy receipt of a live vaccine within 4 weeks prior to randomization receiving mao inhibitor (tranylcypromine, selegiline or phenelzine) receiving pharmacological treatment for a form of multiple sclerosis use of long-term immunosuppressors (ex. tacrolimus, cyclosporin, azathioprine, mycophenolate, sirolimus, methotrexate or chronic use of corticosteroid (> 7.5 mg per day more than 3 months) receiving class ia and class iii anti-arrythmic drugs amiodarone, sotalol, flecainide, propafenone patients receiving or anticipated to receive hydroxychloroquine or azithromycin. prior/concurrent clinical study experience -current enrolment in an interventional arm of a clinical trial with similar endpoints to the cozi trial other exclusions -patients or legal/authorized representatives who refuse to participate to the study.

inclusion criteria confirmed covid-19 (positive polymerase chain reaction (pcr) for covid-19 from any specimen) patients older than 18 years old and younger than 85 years old. bmi higher than 20 but lower than 40 patients with hypoxemia related to viral pneumonia (covid-19) requiring oxygen or nasal high flow therapy (to maintain spo2 above 92%) without criteria for immediate intubation or need for other respiratory supports (cpap, non-invasive ventilation). initiation of oxygen supplementation < 72 hours egfr (ckd epi) > 30 ml/min/1.73m2 serum troponin i < 80 ng/l heart rate ≥ 55 bpm if beta blockers or calcium channel blocker nondihydropyridine are used, and ≥ 60 bpm in the other patients exclusion criteria medical conditions level of care b (unless patient agrees to intubation at study enrollment), c or d (patient admitted for palliative care; or physician is not committed to life-sustaining therapies) no spo2 signal available (only if freeo2 apparatus is used) patient agitation (only if freeo2 apparatus is used) severe untreated sleep apnea history of or currently active primary or secondary immunodeficiency recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, class iii/iv heart failure known presence of mobitz type ii second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker child-pugh score class c pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured during screening persistent hypotension. prior/concomitant therapy receipt of a live vaccine within 4 weeks prior to randomization receiving mao inhibitor (tranylcypromine, selegiline or phenelzine) receiving pharmacological treatment for a form of multiple sclerosis use of long-term immunosuppressors (ex. tacrolimus, cyclosporin, azathioprine, mycophenolate, sirolimus, methotrexate or chronic use of corticosteroid (> 7.5 mg per day more than 3 months) receiving class ia and class iii anti-arrythmic drugs amiodarone, sotalol, flecainide, propafenone patients receiving or anticipated to receive hydroxychloroquine or azithromycin. prior/concurrent clinical study experience -current enrolment in an interventional arm of a clinical trial with similar endpoints to the cozi trial other exclusions -patients or legal/authorized representatives who refuse to participate to the study.

inclusion criteria - confirmed covid-19 (positive polymerase chain reaction (pcr) for covid-19 from any specimen) - patients older than 18 years old and younger than 85 years old. - bmi higher than 20 but lower than 40 - patients with hypoxemia related to viral pneumonia (covid-19) requiring oxygen or nasal high flow therapy (to maintain spo2 above 92%) without criteria for immediate intubation or need for other respiratory supports (cpap, non-invasive ventilation). - initiation of oxygen supplementation < 72 hours - egfr (ckd epi) > 30 ml/min/1.73m2 - serum troponin i < 80 ng/l exclusion criteria medical conditions - level of care b, c or d (patient admitted for palliative care; or physician is not committed to life-sustaining therapies) - no spo2 signal available - patient agitation - severe sleep apnea - history of or currently active primary or secondary immunodeficiency - recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, class iii/iv heart failure - known presence of mobitz type ii second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker - child-pugh score class c - pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured during screening - persistent hypotension. prior/concomitant therapy - receipt of a live vaccine within 4 weeks prior to randomization - receiving mao inhibitor (tranylcypromine, selegiline or phenelzine) - receiving pharmacological treatment for a form of multiple sclerosis - use of long-term immunosuppressors (ex. tacrolimus, cyclosporin, azathioprine, mycophenolate, sirolimus, methotrexate or chronic use of corticosteroid (> 7.5 mg per day more than 3 months) - receiving class 1a and class iii anti-arrythmic drugs amiodarone, sotalol, flecainide, propafenone - patients receiving or anticipated to receive chloroquine or azithromycin. prior/concurrent clinical study experience -current enrolment in an interventional arm of a clinical trial with similar endpoints to the cozi trial other exclusions -patients or legal/authorized representatives who refuse to participate to the study.

inclusion criteria - confirmed covid-19 (positive polymerase chain reaction (pcr) for covid-19 from any specimen) - patients older than 18 years old and younger than 85 years old. - bmi higher than 20 but lower than 40 - patients with hypoxemia related to viral pneumonia (covid-19) requiring oxygen or nasal high flow therapy (to maintain spo2 above 92%) without criteria for immediate intubation or need for other respiratory supports (cpap, non-invasive ventilation). - initiation of oxygen supplementation < 72 hours - egfr (ckd epi) > 30 ml/min/1.73m2 - serum troponin i < 80 ng/l exclusion criteria medical conditions - level of care b, c or d (patient admitted for palliative care; or physician is not committed to life-sustaining therapies) - no spo2 signal available - patient agitation - severe sleep apnea - history of or currently active primary or secondary immunodeficiency - recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, class iii/iv heart failure - known presence of mobitz type ii second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker - child-pugh score class c - pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured during screening - persistent hypotension. prior/concomitant therapy - receipt of a live vaccine within 4 weeks prior to randomization - receiving mao inhibitor (tranylcypromine, selegiline or phenelzine) - receiving pharmacological treatment for a form of multiple sclerosis - use of long-term immunosuppressors (ex. tacrolimus, cyclosporin, azathioprine, mycophenolate, sirolimus, methotrexate or chronic use of corticosteroid (> 7.5 mg per day more than 3 months) - receiving class 1a and class iii anti-arrythmic drugs amiodarone, sotalol, flecainide, propafenone - patients receiving or anticipated to receive chloroquine or azithromycin. prior/concurrent clinical study experience -current enrolment in an interventional arm of a clinical trial with similar endpoints to the cozi trial other exclusions -patients or legal/authorized representatives who refuse to participate to the study.

inclusion criteria - confirmed covid-19 (positive polymerase chain reaction (pcr) for covid-19 from any specimen) - patients older than 18 years old and younger than 85 years old. - bmi higher than 20 but lower than 35 - patients with hypoxemia related to viral pneumonia (covid-19) requiring oxygen therapy below 6 l/min (or fraction of inspired oxygen (fio2) < 0.50) (to maintain spo2 above 92%) without criteria for immediate intubation or need for other respiratory supports (cpap, non-invasive ventilation of high flow nasal therapy). - patients hospital admission < 72 hours - serum creatinine < 124 μmol/l - serum troponin < 28 ng/l exclusion criteria medical conditions - level of care b, c or d (patient admitted for palliative care; or physician is not committed to life-sustaining therapies) - no spo2 signal available - patient agitation - severe sleep apnea - history of or currently active primary or secondary immunodeficiency - recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, class iii/iv heart failure - known presence of mobitz type ii second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker - child-pugh score class c - pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured during screening. prior/concomitant therapy - receipt of a live vaccine within 4 weeks prior to randomization - receiving mao inhibitor (tranylcypromine, selegiline or phenelzine) - receiving pharmacological treatment for a form of multiple sclerosis - use of long-term immunosuppressors (ex. tacrolimus, cyclosporin, azathioprine, mycophenolate, sirolimus, methotrexate; and chronic use of corticosteroid (> 7.5 mg per day more than 3 months) - receiving class 1a and class iii anti-arrythmic drugs amiodarone, sotalol, flecainide, propafenone - patients receiving or anticipated to receive chloroquine or azithromycin. prior/concurrent clinical study experience -current enrolment in a clinical trial with similar endpoints to the cozi trial other exclusions -patients or legal/authorized representatives who refuse to participate to the study.

inclusion criteria - confirmed covid-19 (positive polymerase chain reaction (pcr) for covid-19 from any specimen) - patients older than 18 years old and younger than 85 years old. - bmi higher than 20 but lower than 35 - patients with hypoxemia related to viral pneumonia (covid-19) requiring oxygen therapy below 6 l/min (or fraction of inspired oxygen (fio2) < 0.50) (to maintain spo2 above 92%) without criteria for immediate intubation or need for other respiratory supports (cpap, non-invasive ventilation of high flow nasal therapy). - patients hospital admission < 72 hours - serum creatinine < 124 μmol/l - serum troponin < 28 ng/l exclusion criteria medical conditions - level of care b, c or d (patient admitted for palliative care; or physician is not committed to life-sustaining therapies) - no spo2 signal available - patient agitation - severe sleep apnea - history of or currently active primary or secondary immunodeficiency - recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, class iii/iv heart failure - known presence of mobitz type ii second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker - child-pugh score class c - pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured during screening. prior/concomitant therapy - receipt of a live vaccine within 4 weeks prior to randomization - receiving mao inhibitor (tranylcypromine, selegiline or phenelzine) - receiving pharmacological treatment for a form of multiple sclerosis - use of long-term immunosuppressors (ex. tacrolimus, cyclosporin, azathioprine, mycophenolate, sirolimus, methotrexate; and chronic use of corticosteroid (> 7.5 mg per day more than 3 months) - receiving class 1a and class iii anti-arrythmic drugs amiodarone, sotalol, flecainide, propafenone - patients receiving or anticipated to receive chloroquine or azithromycin. prior/concurrent clinical study experience -current enrolment in a clinical trial with similar endpoints to the cozi trial other exclusions -patients or legal/authorized representatives who refuse to participate to the study.